The journal of allergy and clinical immunology. In practice
-
J Allergy Clin Immunol Pract · Nov 2017
Multicenter StudyTreatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Clinical manifestations of hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) usually begin in childhood, often intensifying during puberty. Currently there are insufficient efficacy/safety data for HAE therapies in children and adolescents due to the small number of pediatric patients enrolled in studies. ⋯ Symptom relief was rapid, and a single icatibant injection in pediatric patients with C1-INH-HAE was well tolerated (ClinicalTrials.gov identifier, NCT01386658).